Curaleaf Earnings + Call Notes
Global cannabis leader reports Q424 results.
$331.1M Revs; est. $332M
$75.8M AEBITDA; est. $75.5M
$157.4M GP; est. $163.3M
($9.3M) OI; est. $18.6M
47.5% GM; est. 49.2%
($77.6M) NI; est. ($53.6M)
($0.10) EPS; est. ($0.07)
"Q4 revenue was $331M, up slightly sequentially. Adj. GM was 48% and aEBITDA was $76M or 23%. We ended the Q4 with $107M in cash on the balance sheet and for the year, generated operating and free cash flow from continuing operations of $163 million and $70 million, respectively.
Over the past two quarters, my primary objective has been to amplify our strengths, address key challenges, and stabilize the business. Having successfully achieved this, we are now forging ahead with our "Return to our ROOTS" initiative—an ambitious strategy centered on driving organic growth, optimizing margins and cash flow, and reducing debt.
With this sharp focus, I am confident that Curaleaf will not only maintain but expand its leadership position. We will build on the strong organic growth seen in our int’l business, Ohio, and New York, while harnessing our innovation pipeline to elevate our product offerings. As we step into 2025, there are tremendous opportunities ahead for Curaleaf."
Boris Jordan, CEO
Call Notes
Keep reading with a 7-day free trial
Subscribe to Cannabis Confidential to keep reading this post and get 7 days of free access to the full post archives.